Contineum Therapeutics
San Diego
About Contineum Therapeutics
Contineum Therapeutics is a clinical-stage biopharmaceutical company that pioneers oral small-molecule therapies for neuroscience, inflammation, and immunology. The company focuses on addressing high unmet needs in these areas, targeting specific biological pathways to impact disease progression. With a pipeline of internally developed programs, including PIPE-791 and PIPE-307, it aims to revolutionize treatment for disorders like idiopathic pulmonary fibrosis and multiple sclerosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $211.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:CTNM
- Website: contineum-tx.com
- Phone: +1.858.333.5280
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/contineum-therapeutics-63400 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.